Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cAd3-EBOZ Ebola Vaccine in Healthy Adults in Switzerland
NCT02289027Phase 2Completed
- Sponsor
- Lausanne University Hospital
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Viral Vectors, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cAd3-EBOV in Ebola virus disease (EVD) (5 arms), sponsored by Lausanne University Hospital. Primary endpoints: Solicited local and systemic reactogenicity signs and symptoms at 7 days, Unsolicited adverse events of all severities at 28 days and 2 more. Started Oct 2014; status: completed.
02
Drugs
cAd3-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on NCT02289027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289027.